Cargando…
Programmed Death Ligand 1; An Immunotarget for Renal Cell Carcinoma
BACKGROUND: In this era of developing targeted therapies and immunotherapies as a treatment for renal cell carcinoma (RCC), Programmed death ligand 1 (PDL1) as a novel biomarker for RCC is analysed in our study. About 90% of all renal cancers are Renal Cell Carcinoma. Most cases are diagnosed incide...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
West Asia Organization for Cancer Prevention
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6982669/ https://www.ncbi.nlm.nih.gov/pubmed/31653140 http://dx.doi.org/10.31557/APJCP.2019.20.10.2951 |